Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Molecular bilayer structure
Patent
1977-09-01
1981-06-09
Fagelson, Anna P.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Molecular bilayer structure
23230B, 250302, 424 1, 424 11, 424 12, 424 13, G01N 3378, G01N 3358, G01N 3354, G01N 2164
Patent
active
042725054
ABSTRACT:
Thyroid hormones such as thyroxine and triiodothyronine are assayed in biological fluid samples by a competitive binding analysis in which a fluorescent label is used. Upon formation of complexes, the fluorescence of the labelled compound is released, and the hormone can be assayed by measuring the fluorescence of the mixture and comparing the result with standard data. Fluorescein is the preferred label. The process can be operated in a continuous flow manner.
REFERENCES:
patent: 3901654 (1975-08-01), Gross
patent: 3940475 (1976-02-01), Gross
patent: 3973129 (1976-08-01), Blumberg
patent: 3992631 (1976-11-01), Harte
patent: 4061466 (1977-12-01), Sjoholm
Nilsson et al., J. Biol. Chem., vol. 250, No. 21, Nov. 1975, pp. 8554-8563.
Williams et al., Methods in Immunol. & Immuno-Chem. Acadamic Press, NY, vol. III, 1971, pp. 427-443.
Technicon, 1972 Technicon Int. Cong., Advances in Automated Analysis, vol. 4, 1973, pp. 87-91.
Fagelson Anna P.
Technicon Instruments Corporation
Tedesco S. P.
LandOfFree
Competitive binding analysis by fluorescence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Competitive binding analysis by fluorescence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Competitive binding analysis by fluorescence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1263888